Management's efforts to optimize commercial performance are evident in Gvoke’s and ... Xeris is zeroing in on the U.S. market ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

After seven months of living and working onboard the International Space Station (ISS), astronauts of NASA's eighth ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, ...

An Eli Lilly official said decades of insulin research and manufacturing ... the second most commonly prescribed medicine to ...